Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03967834 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group

Study acronym: MIRAS
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites revised (20)v21
  2. Study sites: 21 to 20v20
  3. Study sites: 19 to 21v19
  4. Study sites: 18 to 19v18
  5. Study sites: 17 to 18v17
Show 15 earlier versionsHide 15 earlier versions
  1. Study sites: 16 to 17v16
  2. Study sites: 15 to 16v15
  3. Study sites: 14 to 15v14
  4. Primary and study completion dates: Sep 2022 to Apr 2031v13
  5. Study sites: 13 to 14v12
  6. Study sites: 12 to 13v11
  7. Study sites: 11 to 12v10
  8. Study sites: 10 to 11v9
  9. Site details revised at 1 of 10 sitesv8
  10. Study sites: 9 to 10v7
  11. Site details revised at 4 of 9 sitesv6
  12. Start date changed from estimate of Mar 2021 to Apr 26, 2021
    • Site details revised at 1 of 9 sites
    • Eligibility criteria shortened, about 2 words
    v5
  13. Start date: Feb 2021 to Mar 2021v4
  14. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 9 of 9 sites
    v3
  15. Start date: Sep 2019 to Feb 2021v2 Show 5 more changesShow less
    • Primary endpoints: 1 to 2
    • Enrollment target: 500 to 400
    • Study sites: 1 to 9
    • Eligibility criteria expanded, about 161 words
    • Secondary endpoints: 1 to 3
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Institut Claudius Regaud
76 trials monitored
See 4 trials at risk
Sarcoma
1,026 trials monitored
See 67 trials at risk
This trial is a translational, open-label, multi-sites, prospective and retrospective cohort study of 500 patients aimed at clinical and biological characterization of sarcoma of rare subtype. 400 patients will be included in this prospective cohort study; they will be identified in the investigating centers in the context of either routine care or a clinical study protocol. Retrospective cases of patients (100 cases in total) will be identified in all centers through the GSF/GETO clinical databases already setted up (including the clinical base Conticabase).
Trial Details
NCT Number NCT03967834
Lead Sponsor Institut Claudius Regaud
Conditions
(from sponsor)		 Soft Tissue Sarcoma, Clear Cell Sarcoma, Epithelioid Sarcoma, Perivascular Epithelioid Cell Neoplasms, Desmoplastic Small Round Cell Tumor, Malignant Solitary Fibrous Tumors, Alveolar Soft Part Sarcoma, Epithelioid Hemangioendothelioma +2 more
Related terms Desmoplastic Small Round Cell Tumor, Hemangioendothelioma, Epithelioid, Perivascular Epithelioid Cell Neoplasms, Sarcoma, Sarcoma, Alveolar Soft Part, Sarcoma, Clear Cell
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov